Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“For years, KRAS G12D was considered untouchable. Not anymore.
In this phase 1 study published in NEJM, the first-in-class KRAS G12D degrader setidegrasib (ASP3082) was evaluated in previously treated advanced NSCLC and pancreatic cancer harboring KRAS G12D mutations.
Key results at the 600 mg RP2D:
- NSCLC ORR: 36%
- NSCLC median PFS: 8.3 months
- Pancreatic cancer ORR: 24%
- Pancreatic cancer median OS: 10.3 months
My take:
After KRAS G12C, this may represent one of the next major breakthroughs in RAS-targeted therapy.
If confirmed in larger studies, KRAS G12D inhibition could address a major unmet need – potentially becoming a transformative step especially in pancreatic cancer.”
Title: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Authors: Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, and Jonathan W. Goldman.
Other articles featuring Ahmet Dirican on OncoDaily.
